CL2018000377A1 - Mecanismo de resistencia a inhibidores de bromodominio bet - Google Patents
Mecanismo de resistencia a inhibidores de bromodominio betInfo
- Publication number
- CL2018000377A1 CL2018000377A1 CL2018000377A CL2018000377A CL2018000377A1 CL 2018000377 A1 CL2018000377 A1 CL 2018000377A1 CL 2018000377 A CL2018000377 A CL 2018000377A CL 2018000377 A CL2018000377 A CL 2018000377A CL 2018000377 A1 CL2018000377 A1 CL 2018000377A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor
- bromodomain
- cancer
- bet
- resistance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203128P | 2015-08-10 | 2015-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000377A1 true CL2018000377A1 (es) | 2018-07-13 |
Family
ID=57984534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000377A CL2018000377A1 (es) | 2015-08-10 | 2018-02-09 | Mecanismo de resistencia a inhibidores de bromodominio bet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11666580B2 (enExample) |
| EP (2) | EP3334725B1 (enExample) |
| JP (1) | JP2018531891A (enExample) |
| KR (1) | KR20180035905A (enExample) |
| CN (1) | CN108137550A (enExample) |
| AU (2) | AU2016304856B8 (enExample) |
| BR (1) | BR112018002550A2 (enExample) |
| CA (1) | CA2995374A1 (enExample) |
| CL (1) | CL2018000377A1 (enExample) |
| HK (1) | HK1254201A1 (enExample) |
| IL (1) | IL257386A (enExample) |
| MX (1) | MX2018001737A (enExample) |
| PE (1) | PE20181088A1 (enExample) |
| RU (1) | RU2018108165A (enExample) |
| WO (1) | WO2017027571A1 (enExample) |
| ZA (1) | ZA201800969B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | inhibitor resistance mechanism |
| GB201704536D0 (en) * | 2017-03-22 | 2017-05-03 | Univ Malta | Method |
| WO2019032810A2 (en) * | 2017-08-09 | 2019-02-14 | Mayo Foundation For Medical Education And Research | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BETA-INHIBITORY RESISTANT CANCERS |
| CN109503618A (zh) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | 一种brd4抑制剂 |
| CN108084193A (zh) * | 2017-12-19 | 2018-05-29 | 郭守东 | 一种brd4蛋白抑制剂 |
| US12290521B2 (en) | 2018-07-25 | 2025-05-06 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating BET inhibitor-resistant cancers |
| WO2020132259A1 (en) * | 2018-12-21 | 2020-06-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) |
| PT116050B (pt) * | 2020-01-09 | 2022-06-15 | Hovione Farm S A | Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados |
| AU2021298154A1 (en) * | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| JPWO2023157891A1 (enExample) * | 2022-02-16 | 2023-08-24 | ||
| CN114617878A (zh) * | 2022-05-16 | 2022-06-14 | 深圳大学 | Ck2抑制剂在制备抗衰药物中的应用 |
| CN115894678B (zh) * | 2022-07-15 | 2023-10-20 | 新疆赛尔托马斯生物科技有限公司 | 一种干细胞细胞因子的制备方法及其在制备药品中的用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA103867A (en) | 1907-02-01 | 1907-03-05 | Charles M. Thrasher | Nut lock |
| CA120184A (en) | 1908-09-08 | 1909-08-24 | George Albert Thornhill | Bottle labelling machine |
| CA168504A (en) | 1915-01-09 | 1916-03-28 | Carl Lorentz Nilson | Locomotive |
| WO1998047920A1 (en) | 1997-04-18 | 1998-10-29 | Chugai Research Institute For Molecular Medicine, Inc. | Transcriptional regulator |
| EP1077219A4 (en) | 1998-04-30 | 2005-02-23 | Chugai Pharmaceutical Co Ltd | Transcriptional, regulatory factor |
| US20120028912A1 (en) | 2000-02-22 | 2012-02-02 | J.David Gladstone Institute | Methods of modulating bromodomains |
| US6607916B2 (en) | 2001-02-08 | 2003-08-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Casein kinase 2-alpha expression |
| US8522267B2 (en) | 2002-03-08 | 2013-08-27 | Caption Colorado Llc | Method and apparatus for control of closed captioning |
| BRPI0514504A (pt) | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| WO2006065724A2 (en) | 2004-12-14 | 2006-06-22 | Regents Of The University Of Minnesota | Casein kinase 2 antisense therapy |
| WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| WO2008060695A2 (en) | 2006-05-22 | 2008-05-22 | The Trustees Of The University Of Pennsylvania | Antiviral inhibition of casein kinase ii |
| ES2414205T3 (es) | 2006-06-02 | 2013-07-18 | The Ohio State University Research Foundation | Agentes terapéuticos para el tratamiento de linfoma de células del manto |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| CA2683559C (en) | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| WO2009117769A1 (en) | 2008-03-25 | 2009-10-01 | Newcastle Innovation Limited | Inhibition of c-kit cancers |
| JP2012523458A (ja) | 2009-04-13 | 2012-10-04 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | タンパク質ホスファターゼ２ａ活性化剤 |
| US9307184B2 (en) | 2009-07-31 | 2016-04-05 | Echostar Technologies L.L.C. | Multi-user recording allocation |
| US8865901B2 (en) | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2011054851A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Novel process |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| US8862173B2 (en) | 2009-12-10 | 2014-10-14 | Motorola Solutions, Inc. | Method for selecting media for delivery to users at an incident |
| US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| RU2593231C2 (ru) | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Способы лечения с использованием селективных ингибиторов bcl-2 |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| KR101762724B1 (ko) | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US9220706B2 (en) | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
| EP2861255B1 (en) * | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| DE102012212436B4 (de) | 2012-07-16 | 2022-07-14 | Coretronic Corporation | Lichtmodul für eine Projektionsvorrichtung und Verfahren zur Generierung des Blauanteils in einem Lichtmodul für eine Projektionsvorrichtung |
| US20150272970A1 (en) | 2012-09-07 | 2015-10-01 | Carlos Cordon-Cardo | Targeting chemotherapy agent resistance in cancer |
| US20140296218A1 (en) | 2012-10-25 | 2014-10-02 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| US11446309B2 (en) * | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| JP2016538310A (ja) | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| AU2015206194A1 (en) * | 2014-01-20 | 2016-07-28 | Gilead Sciences, Inc. | Therapies for treating cancers |
| WO2016203335A1 (en) * | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | inhibitor resistance mechanism |
-
2016
- 2016-08-10 BR BR112018002550-0A patent/BR112018002550A2/en not_active IP Right Cessation
- 2016-08-10 JP JP2018506976A patent/JP2018531891A/ja active Pending
- 2016-08-10 CN CN201680058347.9A patent/CN108137550A/zh active Pending
- 2016-08-10 EP EP16835823.2A patent/EP3334725B1/en active Active
- 2016-08-10 AU AU2016304856A patent/AU2016304856B8/en active Active
- 2016-08-10 RU RU2018108165A patent/RU2018108165A/ru unknown
- 2016-08-10 MX MX2018001737A patent/MX2018001737A/es unknown
- 2016-08-10 KR KR1020187006573A patent/KR20180035905A/ko not_active Withdrawn
- 2016-08-10 HK HK18113341.9A patent/HK1254201A1/zh unknown
- 2016-08-10 EP EP25171764.1A patent/EP4585273A3/en active Pending
- 2016-08-10 WO PCT/US2016/046318 patent/WO2017027571A1/en not_active Ceased
- 2016-08-10 US US15/751,914 patent/US11666580B2/en active Active
- 2016-08-10 PE PE2018000226A patent/PE20181088A1/es unknown
- 2016-08-10 CA CA2995374A patent/CA2995374A1/en not_active Abandoned
-
2018
- 2018-02-07 IL IL257386A patent/IL257386A/en unknown
- 2018-02-09 CL CL2018000377A patent/CL2018000377A1/es unknown
- 2018-02-13 ZA ZA2018/00969A patent/ZA201800969B/en unknown
-
2021
- 2021-04-20 AU AU2021202388A patent/AU2021202388A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3334725A1 (en) | 2018-06-20 |
| ZA201800969B (en) | 2020-10-28 |
| HK1254201A1 (zh) | 2019-07-12 |
| BR112018002550A2 (en) | 2018-09-18 |
| PE20181088A1 (es) | 2018-07-09 |
| AU2016304856B2 (en) | 2021-01-21 |
| AU2021202388A1 (en) | 2021-05-20 |
| EP4585273A3 (en) | 2025-10-22 |
| MX2018001737A (es) | 2018-09-06 |
| AU2016304856A1 (en) | 2018-03-01 |
| WO2017027571A8 (en) | 2017-04-20 |
| US11666580B2 (en) | 2023-06-06 |
| EP3334725B1 (en) | 2025-04-23 |
| CA2995374A1 (en) | 2017-02-16 |
| IL257386A (en) | 2018-04-30 |
| EP3334725A4 (en) | 2019-07-31 |
| KR20180035905A (ko) | 2018-04-06 |
| WO2017027571A1 (en) | 2017-02-16 |
| RU2018108165A3 (enExample) | 2019-12-25 |
| US20200368248A1 (en) | 2020-11-26 |
| AU2016304856A8 (en) | 2021-02-18 |
| EP4585273A2 (en) | 2025-07-16 |
| RU2018108165A (ru) | 2019-09-12 |
| CN108137550A (zh) | 2018-06-08 |
| AU2016304856B8 (en) | 2021-02-18 |
| JP2018531891A (ja) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001737A (es) | Mecanismo de resistencia a inhibidores de bromodominio bet. | |
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| CY1125213T1 (el) | Μεθοδοι θεραπειας καρκινου του μαστου ar+ | |
| SV2018005677A (es) | Mutaciones puntuales en cancer resistente a trk y metodos relacionados con las mismas | |
| CL2017001209A1 (es) | Inhibidor de cinasa aurora a | |
| MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
| CL2017002983A1 (es) | Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2 | |
| CY1124123T1 (el) | Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου | |
| MX392561B (es) | Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| MX2019007107A (es) | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo. | |
| UY36173A (es) | Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia | |
| EA201791819A1 (ru) | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина | |
| AR094873A1 (es) | Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| BR112016020043A2 (pt) | composições e métodos para a identificação de malignidades de linfócitos b responsivas à terapia de depleção de linfócitos b | |
| CL2018002930A1 (es) | (+)-azasetron para uso en el tratamiento de desórdenes de oído. | |
| MX2019005194A (es) | Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar. |